PharmAust Limited announced that Richard Mollard has been appointed to the role of Chief Scientific Officer. The appointment will take effect from March 13, 2017. Mollard is an experienced pharmaceutical executive with over 15 years in lead scientific roles mainly consulting for companies within the Australian and International Biotechnology sectors. For the past 24 months Mollard has been a consultant to PharmAust, where he has played a key role in the preparation, design and submission of regulatory and clinical documents for PharmAust's human and canine trials. He will now take charge of the clinical and scientific development of monepantel (MPL) at PharmAust and work closely with the newly appointed CEO, Richard Hopkins. In particular Mollard will be preparing for PharmAust's planned Phase II human trial using MPL.